| h-alsmnd-9d07702213f | ATM Kinase Hyperactivation Triggers DNA Damage Response Overflow and p53-Depende | 0.84 | 0.75 | ATM,CHEK2,TP53,BAX,PUMA,BCL2,DNA damage response,oxidative s | validated | 2026-04-27 | |
| h-d5dea85f | Microglial Senescence Prevention via TREM2/SASP Axis | 0.84 | 0.48 | TREM2 | validated | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| h-0ca0f0f8f2 | TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation | 0.84 | 0.82 | TREM2/TYROBP | validated | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| h-var-92a02b86a1 | CREB-Dependent Differential Complement Regulator Positioning for Activity-Based | 0.83 | 0.72 | CREB1, CD55, CD46 | validated | 2026-04-28 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-var-002f522b52 | Activity-Dependent CD55/CD46 Trafficking and Synaptic Surface Localization | 0.83 | 0.72 | CD55 (DAF), CD46 (MCP) | validated | 2026-04-28 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-01685bc3b9 | Differential Complement Regulator Expression on Synaptic Membranes (CD55/CD46) | 0.83 | 0.72 | CD55 (DAF), CD46 (MCP) | validated | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-43f72e21 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue respon | 0.83 | 0.65 | PRKAA1 | validated | 2026-04-02 | sda-2026-04-01-gap-v2-89432b95 |
| h-var-1843e5134a | J-protein co-chaperone system mediates selective autophagy targeting of pathogen | 0.83 | 0.72 | DNAJB6, DNAJB2, HSPA8, HSPA1A, MAP1LC3B, ATG7 | validated | 2026-04-28 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-2dbf5f1f | IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface | 0.83 | 0.78 | IL6R, IL6 | validated | 2026-04-13 | SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9 |
| h-2f3fa14b | Ketone Utilization Index as Metabolic Flexibility Biomarker | 0.83 | 0.40 | HMGCS2 | validated | 2026-04-16 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| h-cross-synth-tdp43- | TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE | 0.83 | 0.86 | TARDBP | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-var-ce41f0efd7 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | 0.83 | 0.75 | TREM2 | validated | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-9e8fc8fd3d | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla | 0.83 | 0.45 | PVALB | validated | 2026-04-16 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-d33964b962 | Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST inter | 0.83 | 0.45 | SST | validated | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-620a7b5b79 | Gamma entrainment repairs cross-regional phase-amplitude coupling via CA1 Schaff | 0.83 | 0.82 | GRIN2A/GRIN2B (NR2A/NR2B NMDA receptors), CAMK2A | validated | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-028af077 | miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy | 0.82 | 0.75 | miR-33/ABCA1 | validated | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-var-a0933e666d | Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuro | 0.82 | 0.76 | AIM2, CASP1, IL1B, PYCARD, TARDBP | validated | 2026-04-05 | SDA-2026-04-01-gap-20260401-225149 |
| h-22d2cfcd | SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via | 0.82 | 0.50 | SIRT1 and PGC1alpha (PPARGC1A) axis | validated | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-alsmnd-e448328ae29 | GLE1-Mediated mRNA Export Defect Creates Translation-Competent mRNA Starvation i | 0.82 | 0.75 | GLE1,DBP10,EXPORTIN-1,XPO1,mRNA export machinery,NPC | validated | 2026-04-27 | |
| h-58e4635a | SASP-Mediated Complement Cascade Amplification | 0.82 | 0.70 | C1Q/C3 | validated | 2026-04-02 | sda-2026-04-01-gap-013 |
| h-c90cca1826 | Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Neuronal Tau Uptake | 0.82 | 0.78 | SULF1/SULF2 | validated | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-var-adfecef68a | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates | 0.82 | 0.78 | NLRP3, CASP1, IL1B, PYCARD | validated | 2026-04-05 | SDA-2026-04-01-gap-20260401-225149 |
| h-6fe30c39bc | STING Antagonists as ALS Therapeutics: Drug Repurposing | 0.82 | 0.68 | STING (TMEM173) | validated | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-856feb98 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | 0.82 | 0.78 | BDNF | validated | 2026-04-02 | SDA-2026-04-03-26abc5e5f9f2 |
| h-ff0d545d | HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase | 0.82 | 0.68 | HSPB1 | validated | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113051-5dce7651 |
| h-b007ca967f | Autophagy-Lysosomal Pathway Dysfunction as a Unifying Proteostasis Failure | 0.82 | 0.78 | TFEB, GBA1, VPS35, TMEM175 | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-cross-synth-snca-s | SNCA conformer propagation across PD, DLB, and MSA | 0.82 | 0.84 | SNCA | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-var-32c4875adb | CYP46A1 Small Molecule Activator Therapy | 0.82 | 0.71 | CYP46A1 | validated | 2026-04-28 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-var-bcf6a16044 | CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stallin | 0.82 | 0.71 | CYP46A1 | validated | 2026-04-28 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-cross-synth-c9orf7 | C9ORF72 autophagy-lysosome collapse across ALS and FTD | 0.82 | 0.83 | C9ORF72 | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-c49c08c56a | Kinetic Modeling Predicts Threshold-Dependent Efficacy—Early Intervention Requir | 0.82 | 0.72 | Seed amplification threshold (RT-QuIC diagnostic) | validated | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| SDA-2026-04-02-gap-t | Extracellular Vesicle Biogenesis Modulation | 0.81 | 0.57 | CHMP4B | validated | 2026-04-16 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-e27f712688 | TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from D | 0.81 | 0.72 | TREM2 | validated | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd |
| h-cross-synth-mapt-t | MAPT tau seeding and release across AD, FTD, and PD-spectrum disease | 0.81 | 0.82 | MAPT | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-5d100034 | SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent N | 0.81 | 0.47 | SLC7A11 (system Xc-) and GPX4 | validated | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-0bcda2e0 | CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerabilit | 0.81 | 0.78 | APOE, CLU | validated | 2026-04-16 | SDA-2026-04-15-gap-debate-20260410-112607-0a3749ea |
| h-var-14d7585dd1 | Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and bl | 0.81 | 0.82 | PVALB | validated | 2026-04-05 | SDA-2026-04-03-26abc5e5f9f2 |
| h-alsmnd-54f981ca6a2 | TIA1 Low-Complexity Domain Oxidation Drives Aberrant Stress Granule Assembly and | 0.81 | 0.75 | TIA1,TDP-43,TARDBP,G3BP1,MAPK1,Oxidative stress response | validated | 2026-04-27 | |
| SDA-2026-04-02-gap-t | LRP1-Dependent Tau Uptake Disruption | 0.81 | 0.72 | LRP1 | validated | 2026-04-16 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-0cbe9bac | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | 0.81 | 0.52 | CSF1R-TREM2 | validated | 2026-04-16 | SDA-2026-04-01-gap-001 |
| h-9268cd08d2 | Thalamocortical Feedforward Inhibition Imposes Rhythm on Glymphatic Waste Cleara | 0.81 | 0.85 | GRIN2B (VB thalamocortical relay neurons); circuit-level tar | validated | 2026-04-28 | SRB-2026-04-28-h-var-e2b5a7e7db |
| h-5b35f7a5 | Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuro | 0.81 | 0.62 | HCAR2 | validated | 2026-04-15 | SDA-2026-04-15-gap-debate-20260410-112330-9abf86eb |
| h-dffb42d9de | Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin | 0.81 | 0.68 | CHI3L1/TREM2/NRGN | validated | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-3b539acf | Neutrophil Extracellular Trap (NET) Inhibition | 0.81 | 0.86 | PADI4 | validated | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-70bc216f06 | p16^INK4a-CCF Axis as Senolytic Timing Biomarker | 0.81 | 0.75 | CDKN2A, CGAS, STING1 | validated | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062101-724971bc |
| h-var-6957745fea | Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration | 0.81 | 0.75 | AIM2, CASP1, IL1B, PYCARD | validated | 2026-04-05 | SDA-2026-04-01-gap-20260401-225149 |
| h-3d545f4e | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | 0.80 | 0.70 | GPR109A | promoted | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| h-cross-synth-trem2- | TREM2-APOE microglial state switching across AD, ALS, and PD | 0.80 | 0.80 | TREM2 | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-var-af9eb8e59b | Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for | 0.80 | 0.75 | AIM2, CASP1, IL1B, PYCARD, PPIF | validated | 2026-04-05 | SDA-2026-04-01-gap-20260401-225149 |
| h-2e03f316 | TREM2-mTOR Co-Agonism for Metabolic Reprogramming | 0.80 | 0.60 | TREM2-mTOR pathway | validated | 2026-04-16 | SDA-2026-04-01-gap-001 |